• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

GlucoTrack provides positive update on next-gen glucose monitor

June 22, 2022 By Sean Whooley

GlucoTrackGlucoTrack (Nasdaq:GCTK) announced today that its second-generation glucose monitor device has shown promising results in analyses.

Rutherford, New Jersey-based GlucoTrack — formerly known as Integrity Applications (Nasdaq:IGAP) — earlier this year completed lab testing of the non-invasive GlucoTrack 2.0 clinical prototype system and has observed better-than-expected accuracy and performance with the technology.

According to a news release, the lab testing process included the testing of multiple iterations of electronics, ear clip and a mobile app with cloud-based software. The company also tested human factors of the mobile app through simulated use in focus groups, plus an external design review for system architecture, stability and cybersecurity.

During in-house testing that followed the bench testing and analyses, GlucoTrack said it observed better thane expected accuracy and performance, with initial data indicating that the GlucoTrack 2.0 may achieve an accuracy comparable to invasive continuous glucose monitors (CGMs) currently available on the market when evaluated in the company’s upcoming first-in-human clinical study.

GlucoTrack will conduct the study at the Rabin Medical Center in Isreal, with initial study results set to drive a follow-up, multi-center study in the U.S., to be led by Dr. Klonoff, Chair of the Company’s Scientific Advisory Board and Medical Director of the Diabetes Research Institute of Mills-Peninsula Medical Center.

The company intends for the U.S. study to represent a precursor to an eventual pivotal trial to be used to garner FDA clearance for the next-generation glucose monitor. The Israel study is slated to begin in the third quarter of this year, with the U.S. study to follow in the fourth quarter.

“I am greatly encouraged by the promising early results of the testing of the Gen 2 clinical prototype system and by the opportunity that lays ahead of us” GlucoTrack President and CEO Paul Goode said in the release. “We thank our shareholders for their encouragement and patience and look forward to providing further updates on our progress.”

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring Tagged With: Glucotrack, integrityapplications

IN CASE YOU MISSED IT

  • Omnipod 5 rollout for type 2 rolls on as Insulet pursues next-gen automation
  • LifePlus reports clinical validation of non-invasive glucose, blood pressure monitor
  • Abbott Diabetes head talks Medtronic partnership, exciting times ahead
  • PharmaSens, SiBionics innovatively combine tech in all-in-one insulin patch pump
  • Study backs Biolinq intradermal sensor in muscle loss prevention during GLP-1 therapy

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS